Conference Day Two

Click on a session title for more details

Registration

Prof Trevor Jones
08:50

Opening remarks from the chair

Prof Trevor Jones, Non Executive Director, SIMBEC-ORION GROUP LTD
Dr Lars Grundemar
09:00

Improving R&D efficiency in reality: focus on exploratory development strategies

Dr Lars Grundemar, Assoc. Vice President, Experimental Medicine and Bioanalysis, Ferring Pharmaceuticals As
Mr Andreas Wallnoefer
09:30

Driving and stimulating research and early development through collaboration and open innovation

Mr Andreas Wallnoefer, Global Head pRED Development, F. Hoffmann - La Roche Ltd
Prof Khusru Asadullah
10:00

Industrial - Academic collaborations for biomarkers

Prof Khusru Asadullah, Professor of Dermatology, University Hospital Charite

Morning refreshments

Biomarkers World Day Two
10:55

Opening remarks from the chair

Dr Jens-Oliver Koopmann, Director, ML Consulting
Biomarkers World Day Two
11:00

Predictive biomarkers for MAGE-A3 cancer immunotherapy: from discovery to implementation in clinical registration studies

Mr Fernando Ulloa Montoya, Director, R&D Cancer Immunotherapies, GSK Vaccines
Exploratory Development Day Two
11:00

Approaches and strategies to bridge the translational gap

Dr Tord Labuda, Senior Principal Scientist, Clinical Science Team Leader, LEO Pharma A/S
Biomarkers World Day Two
11:30

Biomarkers as efficacy for allergy vaccines

Mr Philippe Moingeon, Vice President of Research and Development, Stallergenes
Exploratory Development Day Two
11:30

Validating a pharmacodynamic technique, how valid is valid?

Dr John Connell, Chief Research and Development Officer, MAC Clinical Research
Biomarkers World Day Two
12:00

Biomarker discovery in cardiovascular and metabolic diseases

Prof Pia Davidsson, Ass Director Translational Biomarkers, Translational Science in Cardiovascular and Metabolic Diseases, AstraZeneca
Exploratory Development Day Two
12:00

Effectively extrapolating results of preclinical studies into early phase development to optimise clinical success

Mr Joachim Hochel, Head of Clinical Pharmacokinetics Women's Health Specialized Therapeutics Common Mechanism Research, Bayer Healthcare Pharmaceuticals
Biomarkers World Day One
12:30

Building a translational platform in dermatology

Dr Ulrik Nicolai De Lichtenberg, Senior Principle Scientist, Translational Research, LEO Pharma A/S
Exploratory Development Day Two
12:30

Optimising clinical trials using translational PK/PD

Dr Antje Walz, Head of Quantitative Systems Pharmacology, Roche

Lunch

Biomarkers World Day Two
14:00

How biomarkers facilitated Phase II transition of SAR156597, an anti IL-4/IL-13 antibody for the treatment of IPF

Dr Marie-Laure Ozoux, Head of Biomarkers and Biological Analysis/DSAR, Sanofi
Exploratory Development Day Two
14:00

Transporter-mediated drug-drug interactions that really matter

Dr Jens Rengelshausen, Head Translational Science, Global Early Clinical Development, Grünenthal GmbH
Biomarkers World Day Two
14:30

Overcoming the challenges of biomarker adoption in clinical trials for rare disease treatment

Dr Stergios Moschos, Reader in Industrial Biotechnology, University of Westminster
Exploratory Development Day Two
14:30

Exploratory approaches to determine human ADME properties of drug molecules

Dr Graeme Young, Manager, Drug Metabolism and Pharmacokinetics, Glaxo Smith Kline R & D
Biomarkers World Day Two
15:00

Biomarkers in clinical practice

Ms Devi Nair, Clinical Lead of Clinical Biochemistry and Head of Department, N.H.S. Royal Free London NHS Foundation Trust
Exploratory Development Day Two
15:00

Integrated experimental toxicology strategy to reduce toxicity related attrition

Claudia Stark, Bayer HealthCare
Biomarkers World Day Two
15:30

Personalising post-transplant care: biomarkers of clinical utility in transplantation

Dr Maria Hernandez Fuentes, Senior Lecturer in Translational Research, Kings College London
Exploratory Development Day Two
15:30

Assessing drug induced liver injury during exploratory clinical development

Dr Sif Ormarsdottir, Specialist Gastroenterology and Hepatology, Chair, Hepatotoxicity Safety Knowledge Group,, AstraZeneca Ab
17:30

Closing remarks, end of conference and refreshments

last published: 12/Jun/15 16:38

Co-located with Biomarkers World Europe:

  • Exploratory Clinical Development World Europe 2015